Clinical trials: Resectable Lung Non-Small Cell Carcinoma
NSCLC
The Efficacy and Safety of KN046 Combined With Axitinib
Evaluation of the efficacy of KN046 combined with acitinib as a neoadjuvant therapy for resectable NSCLC through primary pathological response rate and surgical resection rate
- Trial name
- NCT06020352
- Testing
- KN046 plus Axitinib
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Non-Small-Cell Lung Carcinoma, Lung Cancer
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell lung cancer.
- Conditions
- Non-Small-Cell Lung Carcinoma, Lung Cancer, Pulmonary Cancer
- Trial name
- NCT00098085
- Testing
- HSPPC-96
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Agenus Inc.
Carcinoma, Non-Small-Cell Lung
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
- Trial name
- NCT07489066
- Testing
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Stage IIIA Non-Small Cell Lung Cancer
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in predicting response to chemotherapy in patients with stage IIIA non-small cell lung cancer…
- Trial name
- NCT02607423
- Testing
- Cisplatin, Computed Tomography, Docetaxel
- Where
- United States
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non Small Cell Lung Cancer
NADIM II: Neo-Adjuvant Immunotherapy
This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. 90 patients will be enrolled in this trial to examine the pathological Complete Response defined as the absence of residual tumor in lung and…
- Trial name
- NADIMII (NCT03838159)
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 25 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundación GECP
MRD
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer…
- Trial name
- NCT05536505
- Testing
- Adjuvant treatment for MRD positivity
- Where
- 16 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung…
- Trial name
- NCT00367679
- Testing
- Pazopanib
- Where
- 12 sites in United States, Israel and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer, Non-small Cell Carcinoma
Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer
The goal of this randomized controlled clinical trial is to test a 12-week physical activity telecoaching program for NSCLC patients after surgery.
- Trial name
- LucaMove (NCT06057766)
- Testing
- Physical activity tele coaching program
- Where
- 6 sites in Belgium
- Volunteers
- 90 people
- Sponsor
- University Hospital, Ghent
EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable…
- Trial name
- NCT07323056
- Testing
- Sacituzumab Tirumotecan and Limertinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer, Lung Neoplasms
GRN1005 for Brain Metastases From Breast or Lung Cancer
Background: Brain metastases are cancer cells that have spread to the brain from primary cancers in other organs. These tumors can be removed surgically.
- Conditions
- Breast Cancer, Lung Neoplasms, Breast Neoplasms, Lung Cancer
- Trial name
- NCT01679743
- Testing
- Trastuzumab, GRN 1005
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell-Lung
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
The purpose of this study is to evaluate the safety of I-PDT with Temoporfin for patients with Non-Resectable Non-Small-Cell Lung Cancer (NR-NSCLC).
- Trial name
- NCT01637376
- Testing
- Temoporfin
- Where
- United States
- Sponsor
- University of Arkansas
Non Small Cell Lung Cancer, Circulating Tumor Cell
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with…
- Trial name
- NCT05619562
- Testing
- Device for CTC/DTC detection
- Where
- Czechia
- Volunteers
- 166 people
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Non-Small Cell Lung Cancer
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02927301
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Where
- 19 sites in United States
- Volunteers
- 181 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with…
- Trial name
- NCT05577702
- Testing
- Tislelizumab, Ociperlimab, Alcestobart
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- BeiGene
Resectable Non-small Cell Lung Cancer
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
This open-label, single-arm study is designed to evaluate the safety and preliminary efficacy of NK010 cell injection combined with a PD-1 antibody and platinum-based chemotherapy as neoadjuvant therapy in patients with…
- Trial name
- NCT07318636
- Testing
- PD-1 antibody, NK010
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Resectable Stage II-IIIB NSCLC
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
In recent years, substantial progress has been made in the development of perioperative immunotherapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT07108816
- Testing
- Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab
- Volunteers
- 52 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Carcinoma, Non-Small-Cell Lung
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
This is a two-arm, randomized, multicenter phase II clinical study to evaluate the efficacy and safety of the Iparomlimab and Tuvonralimab combined with 2 or 4 cycles of chemotherapy as neoadjuvant therapy for resectable stage…
- Trial name
- NCT07129161
- Testing
- 4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 2 cycles (Platinum-based doublet chemotherapy), 4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 4 cycles (Platinum-based doublet chemotherapy)
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer Stage IIIA
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or cisplatin + pemetrexed) as neoadjuvant therapy to…
- Trial name
- ANSWER (NCT04455594)
- Testing
- Almonertinib, Erlotinib, Cisplatin
- Where
- China
- Volunteers
- 168 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University